FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1899609246> ?p ?o ?g. }

• W1899609246 endingPage "1932" @default.
• W1899609246 startingPage "1918" @default.
• W1899609246 abstract "To compare the efficacy of high-dose (3,600 mg/day) vs low-dose (1,200 mg/day) oral gabapentin enacarbil (GEn) on pain intensity in adults with postherpetic neuralgia (PHN) and a history of inadequate response to ≥1,800 mg/day gabapentin. Multicenter, randomized, double-blind, crossover study (NCT00617461). Thirty-five outpatient centers in Germany and the United States. Subjects aged ≥18 years with a diagnosis of PHN. During a 2-week baseline period, subjects received open-label treatment with 1,800 mg/day gabapentin. Subjects who had a mean 24-hour average pain intensity score ≥4 during the last 7 days of the baseline period were randomized to receive GEn (1,200 or 3,600 mg/day) for treatment period 1 (28 days), followed by GEn 2,400 mg/day (4 days), and the alternate GEn dose for treatment period 2 (28 days). There was a modest but significant improvement in pain intensity scores with GEn 3,600 mg vs 1,200 mg (adjusted mean [90% confidence interval] treatment difference, −0.29 [−0.48 to −0.10]; P = 0.013). The difference in efficacy between doses was observed primarily in subjects who received the higher dose during treatment period 2; certain aspects of the study design may have contributed to this outcome. Plasma steady-state gabapentin exposure during GEn treatment was as expected and consistent between treatment periods. No new safety signals or adverse event trends relating to GEn exposure were identified. While the overall results demonstrated efficacy in a PHN population, the differences between treatment periods confound the interpretation. These findings could provide insight into future trial designs." @default.
• W1899609246 created "2016-06-24" @default.
• W1899609246 creator A5005769283 @default.
• W1899609246 creator A5009268783 @default.
• W1899609246 creator A5010764606 @default.
• W1899609246 creator A5012659682 @default.
• W1899609246 creator A5022227420 @default.
• W1899609246 creator A5025657339 @default.
• W1899609246 creator A5027964069 @default.
• W1899609246 creator A5029308799 @default.
• W1899609246 creator A5034241161 @default.
• W1899609246 creator A5042650639 @default.
• W1899609246 creator A5055340840 @default.
• W1899609246 creator A5056248574 @default.
• W1899609246 creator A5067939471 @default.
• W1899609246 creator A5084004841 @default.
• W1899609246 date "2013-12-01" @default.
• W1899609246 modified "2023-09-25" @default.
• W1899609246 title "A Phase 2a, Randomized, Crossover Trial of Gabapentin Enacarbil for the Treatment of Postherpetic Neuralgia in Gabapentin Inadequate Responders" @default.
• W1899609246 cites W1495495369 @default.
• W1899609246 cites W1535948728 @default.
• W1899609246 cites W164385564 @default.
• W1899609246 cites W1973819547 @default.
• W1899609246 cites W1976891250 @default.
• W1899609246 cites W1980107617 @default.
• W1899609246 cites W1988364618 @default.
• W1899609246 cites W2000366380 @default.
• W1899609246 cites W2003184201 @default.
• W1899609246 cites W2003396378 @default.
• W1899609246 cites W2003520913 @default.
• W1899609246 cites W2004621676 @default.
• W1899609246 cites W2014380747 @default.
• W1899609246 cites W2027339686 @default.
• W1899609246 cites W2039665714 @default.
• W1899609246 cites W2039982019 @default.
• W1899609246 cites W2044717963 @default.
• W1899609246 cites W2053060152 @default.
• W1899609246 cites W2055967275 @default.
• W1899609246 cites W2057983296 @default.
• W1899609246 cites W2062312183 @default.
• W1899609246 cites W2073543688 @default.
• W1899609246 cites W2081154281 @default.
• W1899609246 cites W2092734723 @default.
• W1899609246 cites W2103475556 @default.
• W1899609246 cites W2108028505 @default.
• W1899609246 cites W2124146642 @default.
• W1899609246 cites W2132309748 @default.
• W1899609246 cites W2135227200 @default.
• W1899609246 cites W2150775151 @default.
• W1899609246 cites W2152734304 @default.
• W1899609246 cites W2158458087 @default.
• W1899609246 cites W2159977024 @default.
• W1899609246 cites W2322450883 @default.
• W1899609246 cites W2331364533 @default.
• W1899609246 cites W3194956376 @default.
• W1899609246 cites W4254230094 @default.
• W1899609246 doi "https://doi.org/10.1111/pme.12227" @default.
• W1899609246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24102928" @default.
• W1899609246 hasPublicationYear "2013" @default.
• W1899609246 type Work @default.
• W1899609246 sameAs 1899609246 @default.
• W1899609246 citedByCount "8" @default.
• W1899609246 countsByYear W18996092462014 @default.
• W1899609246 countsByYear W18996092462016 @default.
• W1899609246 countsByYear W18996092462017 @default.
• W1899609246 countsByYear W18996092462019 @default.
• W1899609246 countsByYear W18996092462020 @default.
• W1899609246 crossrefType "journal-article" @default.
• W1899609246 hasAuthorship W1899609246A5005769283 @default.
• W1899609246 hasAuthorship W1899609246A5009268783 @default.
• W1899609246 hasAuthorship W1899609246A5010764606 @default.
• W1899609246 hasAuthorship W1899609246A5012659682 @default.
• W1899609246 hasAuthorship W1899609246A5022227420 @default.
• W1899609246 hasAuthorship W1899609246A5025657339 @default.
• W1899609246 hasAuthorship W1899609246A5027964069 @default.
• W1899609246 hasAuthorship W1899609246A5029308799 @default.
• W1899609246 hasAuthorship W1899609246A5034241161 @default.
• W1899609246 hasAuthorship W1899609246A5042650639 @default.
• W1899609246 hasAuthorship W1899609246A5055340840 @default.
• W1899609246 hasAuthorship W1899609246A5056248574 @default.
• W1899609246 hasAuthorship W1899609246A5067939471 @default.
• W1899609246 hasAuthorship W1899609246A5084004841 @default.
• W1899609246 hasBestOaLocation W18996092461 @default.
• W1899609246 hasConcept C126322002 @default.
• W1899609246 hasConcept C142724271 @default.
• W1899609246 hasConcept C168563851 @default.
• W1899609246 hasConcept C197934379 @default.
• W1899609246 hasConcept C204787440 @default.
• W1899609246 hasConcept C27081682 @default.
• W1899609246 hasConcept C2776608144 @default.
• W1899609246 hasConcept C2777107010 @default.
• W1899609246 hasConcept C2778866549 @default.
• W1899609246 hasConcept C2780016216 @default.
• W1899609246 hasConcept C2908647359 @default.
• W1899609246 hasConcept C42219234 @default.
• W1899609246 hasConcept C44249647 @default.
• W1899609246 hasConcept C71924100 @default.
• W1899609246 hasConcept C87813604 @default.

• next